The utility of laboratory monitoring among patients with acne vulgaris receiving different doses of oral isotretinoin
Elena Zanganeh, Seyedali Seyedmajidi, Shahin Hajiebrahimi, Anahita Ahmadi, Seyed Ashkan Hosseini, Mehdi Alimadadi, Mohammadreza Seyyedmajidi
Abstract:Background and study aim: Adverse events of isotretinoin are in mucocutaneous and hepatic tissues, alterations in lipid levels and teratogenicity. This study was aimed to evaluate the alterations in aminotransferases and serum lipids in patients using different doses of oral isotretinoin.Patients and methods: 300 patients with moderate to severe acne were enrolled and randomized to receive isotretinoin for 24 weeks in three groups: 40 mg daily (group A: continuous conventional dose), 20 mg daily (group B: continuous low dose) or 40 mg daily for one week out of every 4 weeks (group C: intermittent dose). Baseline liver enzymes and lipid profile were done and repeated at 4,12 and 24 weeks after starting. Results: There were no statistical differences in the patients in sex, age and body mass index (BMI) in three groups. Only in group A, there was a non-significant increase in serum triglyceride (p=0.17) and non-significant decrease in HDL after 12 weeks of treatment (p=0.36). Both AST and ALT increased non-significantly after 4 weeks of treatment in this group (p=0.09). No difference was seen in serum lipids and liver aminotransferases during the study in group B and C.Conclusion: The results showed that use of oral isotretinoin for the treatment of acne did not lead to permanent and significant change in serum lipids, ALT and AST levels and these alterations did not require treatment to be interrupted. Laboratory monitoring is not necessary among patients receiving intermittent or continuous low dose of oral isotretinoin.
Elena Zanganeh, Seyedali Seyedmajidi, Shahin Hajiebrahimi, Anahita Ahmadi, Seyed Ashkan Hosseini, Mehdi Alimadadi, Mohammadreza Seyyedmajidi. The utility of laboratory monitoring among patients with acne vulgaris receiving different doses of oral isotretinoin. Int. J. Dermatol. Res. 2021;3(1):12-14. DOI: 10.33545/26646471.2021.v3.i1a.33